Itraconazol Actavis (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By preventing ergosterol formation, the drug disrupts the integrity of the fungal cell membrane, inhibiting growth and leading to cell death. This mechanism is effective against a wide range of yeasts and molds.

The dosage of itraconazole is individualized by the prescribing clinician according to the infection type, severity, patient weight, age, and renal or hepatic function. Dosing regimens can vary from a single daily dose to divided doses, and the prescriber determines the appropriate schedule and duration.

Itraconazole is classified as pregnancy category unknown, and its safety has not been established in pregnant or nursing women. Health professionals generally advise avoiding the drug during pregnancy and lactation unless the potential benefit justifies the potential risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Itraconazol Actavis. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itraconazole offers a broad spectrum of activity against dermatophytes, yeasts and molds, and it has a higher tissue penetration in skin, nails and lungs compared with fluconazole. However, it is metabolized by CYP3A4 and therefore has more potential for drug interactions than some newer azoles such as posaconazole.

Store the product at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not expose the capsules to excessive heat or humidity, and keep them out of reach of children. Follow any additional handling instructions provided on the label.

Itraconazol Actavis is administered orally, typically as a capsule taken with food or a full glass of water to enhance absorption. The exact administration schedule, including whether it is taken once daily or divided doses, is determined by the prescribing clinician based on the infection being treated.

Serious adverse events include hepatotoxicity (elevated liver enzymes or liver failure), severe skin reactions such as Stevens‑Johnson syndrome, cardiac failure in patients with pre‑existing heart disease, and rare visual disturbances. Patients should report any signs of liver injury, rash, shortness of breath or vision changes promptly.

Itraconazole is contraindicated in individuals with known hypersensitivity to itraconazole or any azole antifungal, in patients with severe liver impairment, and in those taking strong CYP3A4 inducers that could markedly reduce drug exposure. Caution is also advised for patients with existing heart failure.